CA Patent

CA3062972C — Indolizine derivatives and their application in medicine

Assigned to Kind Pharmaceutical LLC · Expires 2021-09-14 · 5y expired

What this patent protects

This invention belongs to the field of medicine and relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses substituted indolizine derivatives of formula I, or an optical isomer thereof, a geometric isomer thereof, a tautomer th…

USPTO Abstract

This invention belongs to the field of medicine and relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses substituted indolizine derivatives of formula I, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof. The substituted indolizine derivatives are used as a HIF prolyl hydroxylase inhibitor to fill the gap where no HIF prolyl hydroxylase inhibitor drugs associated with HIFs have been approved for market entry, which are used for treating or preventing a disease associated with HIFs such as anemia. Thus, the invention also relates to the use of these compounds in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
CA3062972C
Jurisdiction
CA
Classification
—
Expires
2021-09-14
Drug substance claim
No
Drug product claim
No
Assignee
Kind Pharmaceutical LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.